Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406411 | 0.83 | ITGAV (0.51) | LMNAHDAC6HDAC1HDAC8ALDH1A1 | |
| SCHEMBL2407401 | 0.82 | SLC1A3 (0.48) | ADAM17HDAC6HDAC1HDAC8HDAC3 | |
| SCHEMBL2408499 | 0.81 | ITGAV (0.50) | LMNAHDAC6HDAC1HDAC8ALDH1A1 | |
| SCHEMBL12280416 | 0.79 | HDAC1 (0.43) | LMNAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL2407977 | 0.79 | MMP7 (0.52) | LMNAKAT6AHDAC6HDAC1HDAC8 | |
| SCHEMBL2412830 | 0.78 | POLB (0.56) | LMNAPOLBHDAC6HDAC1HDAC8 | |
| SCHEMBL2409531 | 0.77 | CNR2 (0.43) | LMNAHDAC6HDAC1HDAC8ALDH1A1 | |
| SCHEMBL2407384 | 0.76 | MEN1 (0.53) | LMNAADAM17POLBHDAC6HDAC1 | |
| SCHEMBL16000126 | 0.74 | LMNA (0.54) | LMNAADAM17POLBKAT6AHDAC1 | |
| SCHEMBL2413258 | 0.74 | HDAC6 (0.49) | LMNAADAM17HDAC6HDAC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2011106632-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | LMNA 2259/4885ADAM17 1488/4885POLB 539/4885 |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | LMNA 2259/4885ADAM17 1488/4885POLB 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.